05601nam 2200733 450 991013220530332120200520144314.01-118-69789-81-118-69719-71-118-69791-X(CKB)3710000000106462(EBL)1683802(SSID)ssj0001195731(PQKBManifestationID)11703175(PQKBTitleCode)TC0001195731(PQKBWorkID)11161113(PQKB)10802183(OCoLC)867001315(MiAaPQ)EBC1683802(DLC) 2013051083(Au-PeEL)EBL1683802(CaPaEBR)ebr10867125(CaONFJC)MIL604408(OCoLC)879074476(PPN)190664223(EXLCZ)99371000000010646220140515h20142014 uy 0engur|n|---|||||txtccrLigand design in medicinal inorganic chemistry /edited by Tim Storr ; contributors Peter J. Barnard [and thirty seven others]Chichester, England :Wiley,2014.©20141 online resource (493 p.)Description based upon print version of record.1-118-48852-0 Includes bibliographical references at the end of each chapters and index.Cover; Title Page; Copyright; Contents; About the Editor; List of Contributors; Chapter 1 Introduction to Ligand Design in Medicinal Inorganic Chemistry; References; Chapter 2 Platinum-Based Anticancer Agents; 2.1 Introduction; 2.2 The advent of platinum-based anticancer agents; 2.3 Strategies for overcoming the limitations of cisplatin; 2.4 The influence of ligands on the physicochemical properties of platinum anticancer complexes; 2.4.1 Lipophilicity; 2.4.2 Reactivity; 2.4.3 Rate of reduction; 2.5 Ligands for enhancing the anticancer activity of platinum complexes2.5.1 Ligands for improving DNA affinity2.5.2 Ligands for inhibiting enzymes; 2.6 Ligands for enhancing the tumour selectivity of platinum complexes; 2.6.1 Ligands for targeting transporters; 2.6.2 Ligands for targeting receptors; 2.6.3 Ligands for targeting the EPR effect; 2.6.4 Ligands for targeting bone cancer; 2.7 Ligands for photoactivatable platinum complexes; 2.8 Conclusions; References; Chapter 3 Coordination Chemistry and Ligand Design in the Development of Metal Based Radiopharmaceuticals; 3.1 Introduction; 3.1.1 Metals in nuclear medicine3.1.2 The importance of coordination chemistry3.1.3 Overview; 3.2 General metal based radiopharmaceutical design; 3.2.1 Choice of radionuclide; 3.2.2 Production of the radiometal starting materials; 3.2.3 Ligand and chelate design consideration; 3.3 Survey of the coordination chemistry of radiometals applicable to nuclear medicine; 3.3.1 Technetium; 3.3.2 Rhenium; 3.3.3 Gallium; 3.3.4 Indium; 3.3.5 Yttrium and lanthanides; 3.3.6 Copper; 3.3.7 Zirconium; 3.3.8 Scandium; 3.3.9 Cobalt; 3.4 Conclusions; References; Chapter 4 Ligand Design in d-Block Optical Imaging Agents and Sensors4.1 Summary and scope4.2 Introduction; 4.2.1 Criteria for biological imaging optical probes; 4.3 Overview of transition-metal optical probes in biomedicinal applications; 4.3.1 Common families of transition metal probes; 4.4 Ligand design for controlling photophysics; 4.4.1 Photophysical processes in transition metal optical imaging agents and sensors; 4.4.2 Photophysically active ligand families-tuning electronic levels; 4.4.3 Ligands which control photophysics through indirect effects; 4.4.4 Transition metal optical probes with carbonyl ligands; 4.5 Ligand design for controlling stability4.6 Ligand design for controlling transport and localisation4.6.1 Passive diffusion; 4.6.2 Active transport; 4.7 Ligand design for controlling distribution; 4.7.1 Mitochondrial-targeting probes; 4.7.2 Nuclear-targeting probes; 4.7.3 Bioconjugation; 4.8 Selected examples of ligand design for important individual probes; 4.8.1 A pH-sensitive ligand to control Ir luminescence; 4.8.2 Dimeric NHC ligands for gold cyclophanes; 4.9 Transition metal probes incorporating or capable of more than one imaging mode; 4.9.1 Bimodal MRI/optical probes; 4.9.2 Bimodal radio/optical probes4.9.3 Bimodal IR/optical probesIncreasing the potency of therapeutic compounds, while limiting side-effects, is a common goal in medicinal chemistry. Ligands that effectively bind metal ions and also include specific features to enhance targeting, reporting, and overall efficacy are driving innovation in areas of disease diagnosis and therapy. Ligand Design in Medicinal Inorganic Chemistry presents the state-of-the-art in ligand design for medicinal inorganic chemistry applications. Each individual chapter describes and explores the application of compounds that either target a disease site, or are activatedDNA-drug interactionsLigand binding (Biochemistry)DrugsDesignPharmaceutical chemistryDNA-drug interactions.Ligand binding (Biochemistry)DrugsDesign.Pharmaceutical chemistry.612/.01524Storr TimBarnard Peter J.MiAaPQMiAaPQMiAaPQBOOK9910132205303321Ligand design in medicinal inorganic chemistry2034117UNINA02252oam 2200685I 450 991097259240332120251117070125.00-429-91561-60-429-90138-00-429-47661-21-283-12497-197866131249751-84940-186-1(CKB)2670000000094803(EBL)712310(OCoLC)729167053(SSID)ssj0000523832(PQKBManifestationID)12223046(PQKBTitleCode)TC0000523832(PQKBWorkID)10545416(PQKB)10371289(MiAaPQ)EBC712310(Au-PeEL)EBL712310(CaPaEBR)ebr10477668(CaONFJC)MIL312497(OCoLC)738434107(FlBoTFG)9780429476617(EXLCZ)99267000000009480320181122h20181995 uy 0engur||| |||||txtccrLearning Consultation A Systemic Framework /by David CampbellFirst edition.Boca Raton, FL :Routledge,[2018].©1995.1 online resource (179 p.)Systemic thinking and practice series. Work with organizationsDescription based upon print version of record.0-367-10482-2 1-85575-117-8 Includes bibliographical references and index.pt. 1. The seminars -- pt. 2. The applications.A book which will illuminate the learning process from the perspective of the teacher as well as the learner. The experiences of the various contributors will empower the reader to take more personal risks in their own learning.Systemic thinking and practice series.Work with organizations.LearningOrganizational learningLearning.Organizational learning.658.4/6668.4601Campbell David344552FlBoTFGFlBoTFGBOOK9910972592403321Learning Consultation4483781UNINA